Drug discovery and NCEs

In 2018 FDA has approved 34 new drugs which are presently in the market. Each year, CDER approves series of new drugs and biological products. Some of these products are often innovative new products that never before have been used in clinical practice. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. According to Medscape the ratio of researched drugs to eventually approved therapies at between 5,000-to-1 and 10,000-to-1. Nonetheless, if a drug manages to gain FDA approval, the cumulative direct and indirect expenses are huge.  As per estimated study performed by a well-known university, the true cost to bring a drug to market was US$2.56 billion. This figure is inclusive of just shy of $1.4 billion in average out-of-pocket costs to the drug developer, as well as $1.16 billion in time costs, which are essentially the expected returns that investors forgo while a drug is in development.

 

  • Computer Aided Drug Design (CADD)
  • Insilco Drug Discovery
  • Novel Detection Technologies and Drug Discovery
  • New Chemical Entity Exclusivity Determinations
  • Statutory and regulatory framework
  • NME versus NCE

Related Conference of Drug discovery and NCEs

October 25-26, 2019

14th International Conference on Biopharma and Biotherapeutics

| Copenhagen, Denmark
October 23-24, 2019 | Copenhagen, Denmark

12th Pharma Congress

September 11-12, 2019

2nd Annual Pharmaceutical Biotechnology Congress

Singapore
November 11-12, 2019

20th Annual Pharma Middle East Congress

Renaissance Polat Istanbul Hotel | Istanbul, Turkey
November 18-19, 2019

European Congress on Nanomedicine and Pharmaceutical Nanotechnology

Prague, Czech Republic
November 18-19, 2019

European Conference on Pharmacovigilance & Drug Safety

Prague, Czech Republic
December 02, 03, 2019

15th Annual Congress on Pharmacology and Toxicology

Paris, France
February 12-13, 2020

14th Global Pharmacovigilance and Clinical Trials Summit

Sydney, Australia
February 12-13, 2020

2nd International Conference on Biosimilars & Pharmaceuticals

Auckland, New Zealand
March 25-26, 2020

23rd Asia Pacific Pharma Congress

Singapore
April 01-02, 2020

13th European Biosimilars Congress 2020

London, UK
April 09-10, 2020

World Pharma Expo

Bangkok, Thailand
April 27-28, 2020

5th Pharmaceutical Chemistry Conference

Prague, Czech Republic
April 27-28, 2020

7th European Biopharma Congress

Prague, Czech Republic
May 06-07, 2020

15th Annual Meet on Euro Ethnopharmacology

Prague | Czech Republic
May 18-19, 2020

30th Annual European Pharma Congress

Berlin, Germany
May 27- 28, 2020

14 th World Drug Delivery Summit

| London, UK
June 15-16, 2020

cancer-research-2020

Barcelona, Spain
August 26-27, 2020

33rdWorld Congress on Pharmacology

Barcelona, Spain
September 07-08, 2020

Global Summit on Generic Drugs and Quality Control

| Prague, Czech Republic
September 10-11, 2020

World Congress on Rare Diseases & Orphan Drugs

| Prague, Czech Republic
September 21-22, 2020

35th World Pharmacology and Toxicology Forum

Tokyo, Japan
October 19-20, 2020

Innovation in Drug Design Techniques and Pharmacology

| Paris, France
December 02-03, 2020

International Conference onBiotechnology and Healthcare

Auckland, Newzealand
December 06-07, 2021

22nd Pharma Middle East Congress

Dubai, UAE

Drug discovery and NCEs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in